Fifth Annual In-House Counsel & Regulatory Forum on

Advertising Law For The Pharmaceutical Industry

Avoiding regulatory and political scrutiny while communicating a clear message through any medium

Tuesday, January 23, 2007

About

Safeguard your client's ads from consumer fraud and false advertising claims!

Pharmaceutical advertising is more challenging than ever in the wake of new regulatory and political schemes. Recognizing the power of DTC advertising through online mechanisms, the pharmaceutical industry will increase online advertising spending by about 25% this year, to $780 million. With this increase comes heightened scrutiny from regulatory and legislative bodies.

It is your duty to ensure best advertising practices for your client.

Whether advertising online or through other means, the only way to achieve the above is with a thorough understanding of the FDA, the NAD, state governments, the FDCA, and the Lanham Act. You must be sure to know how promoting a drug can trigger potential issues in conjunction with these governing bodies and laws.

Design, implement, and carry out best practices in pharmaceutical advertising that will benefit your company and most importantly, the health of your consumers.

The publication from the revamped American Conference Institute's Drug Advertising & Promotions conference, will provide you with a thorough understanding of advertising law for your industry.

Have access to the conference materials from leading pharmaceutical attorneys who are entrenched in advertising law, and representatives from the regulatory bodies who are called upon to review ads for improper advertising and promotion practices. Specific highlights include:

  • Avoiding consumer fraud and false advertising
  • Understanding the FDA's role in disease awareness advertising
  • Advertising pharmaceuticals online what to watch out for
  • Using the Lanham Act in conjunction with detailing

Contents & Contributors

About

Safeguard your client's ads from consumer fraud and false advertising claims!

Pharmaceutical advertising is more challenging than ever in the wake of new regulatory and political schemes. Recognizing the power of DTC advertising through online mechanisms, the pharmaceutical industry will increase online advertising spending by about 25% this year, to $780 million. With this increase comes heightened scrutiny from regulatory and legislative bodies.

It is your duty to ensure best advertising practices for your client.

Whether advertising online or through other means, the only way to achieve the above is with a thorough understanding of the FDA, the NAD, state governments, the FDCA, and the Lanham Act. You must be sure to know how promoting a drug can trigger potential issues in conjunction with these governing bodies and laws.

Design, implement, and carry out best practices in pharmaceutical advertising that will benefit your company and most importantly, the health of your consumers.

The publication from the revamped American Conference Institute's Drug Advertising & Promotions conference, will provide you with a thorough understanding of advertising law for your industry.

Have access to the conference materials from leading pharmaceutical attorneys who are entrenched in advertising law, and representatives from the regulatory bodies who are called upon to review ads for improper advertising and promotion practices. Specific highlights include:

  • Avoiding consumer fraud and false advertising
  • Understanding the FDA's role in disease awareness advertising
  • Advertising pharmaceuticals online what to watch out for
  • Using the Lanham Act in conjunction with detailing

Contents & Contributors


OBTAINING FDA PRE-APPROVAL FOR PROMOTIONS
Joseph Leghorn, Nixon Peabody LLP.

DISEASE AWARENESS ADVERTISEMENTS: GETTING THEM RIGHT
Beth A. Krewson, GlaxoSmithKline
Meredith Manning, Hogan & Hartson

ADVERTISING PHARMACEUTICALS ONLINE - WHAT TO WATCH OUT FOR
Joseph P. McMenamin, McGuire Woods LLP

DISSEMINATION OF CLINICAL TRIAL RESULTS: REGULATORY AND STATUTORY COMPLIANCE VS. OFFLINE PROMOTION
Howard Dorfman, Bayer Healthcare LLC

ETHICAL CONSIDERATIONS IN PHARMACEUTICAL ADVERTISING
Don S. McKinney, Adams & Reese LLP

THE EFFECT OF PREEMPTION ON PHARMACEUTICAL ADVERTISING
Marilyn Moberg, Reed Smith LLP
David Bloch, Reed Smith LLP

THE ENZI-KENNEDY FDA REFORM LEGISLATION POTENTIAL NEW LIMITATIONS ON PHARMACEUTICAL DIRECT-TO-CONSUMERADVERTISING
Stephen Northrup, Arent Fox

MAKING AND CHALLENGING COMPARATIVE ADVERTISING CLAIMS
David Mallen, National Advertising Division

ADVERTISING LAW FOR THE PHARMACEUTICAL INDUSTRY COMPLIANCE CLAIMS
Michael Labson, Covington & Burling LLP

THE RELEVANCE OF FDA REGULATION TO LANTHAM ACT CHALLENGES INVOLVING DRUG PROMOTION
Harold P. Weinberger, Kramer Levin LLP

NEW DEVELOPMENTS IN REDUCING MEDICATION ERRORS IN MEDICAL COMMUNICATIONS
Coleen Klasmeier, Sidley Austin LLP

TRADEMARKS AND MEDICATION SAFETY
Robert E. Lee, Eli Lilly & Company

THE SCOPE AND SOURCE OF MEDICATION ERRORS
George DiDomizio, Gemini Trademark Services



DOCUMENT TYPES: PRESENTATIONS AVAILABLE: 0